Mitchall G. Clark Sells 2,995 Shares of Atara Biotherapeutics Inc. (ATRA) Stock
Atara Biotherapeutics Inc. (NASDAQ:ATRA) insider Mitchall G. Clark sold 2,995 shares of Atara Biotherapeutics stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $19.53, for a total value of $58,492.35. Following the sale, the insider now owns 98,182 shares of the company’s stock, valued at $1,917,494.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 18.05 on Monday. The firm’s market capitalization is $520.92 million. The firm has a 50-day moving average price of $16.82 and a 200-day moving average price of $19.56. Atara Biotherapeutics Inc. has a one year low of $12.45 and a one year high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. Equities analysts anticipate that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in Atara Biotherapeutics during the third quarter worth approximately $110,000. BlackRock Group LTD increased its position in Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock worth $119,000 after buying an additional 198 shares during the last quarter. BlackRock Inc. increased its position in Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the last quarter. Institutional investors and hedge funds own 74.45% of the company’s stock.
Several equities analysts have issued reports on the company. Jefferies Group reiterated a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 10th. Citigroup Inc. lifted their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a report on Friday, August 19th. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Sunday, November 6th. Three analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $25.86.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.